Leqvio (Inclisiran) Medicaid Coverage by State Tier: 2026 Complete Guide

What Is Inclisiran and Why Does Medicaid Tier Placement Matter?

Inclisiran is the first small-interfering RNA (siRNA) approved for LDL-C lowering. The FDA granted approval on December 22, 2021, for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) [1]. Unlike statins taken daily or PCSK9 monoclonal antibodies injected every 2 to 4 weeks, inclisiran is administered by a healthcare provider twice yearly after the initial loading doses, which changes its cost structure considerably.

Because inclisiran is provider-administered and billed under the medical benefit at infusion centers or physician offices, some state Medicaid programs classify it as a medical-benefit drug rather than a pharmacy-benefit drug. That distinction controls which utilization-management rules apply.

Why Tier Placement Affects Your Cost

State Medicaid programs set preferred drug lists (PDLs). A "preferred" tier means low or zero cost-sharing; a "non-preferred specialty" tier can mean prior authorization, step therapy, and higher copays. The Centers for Medicare and Medicaid Services (CMS) requires state Medicaid programs to cover all drugs in each USPHS drug category, but states retain significant latitude to manage utilization through these tools [2].

The 2026 Coverage Field

As of January 2026, an estimated 28 to 32 states cover inclisiran under at least one Medicaid benefit (pharmacy or medical). That figure is fluid. CMS rebate negotiations and state supplemental rebate agreements with Novartis directly influence whether a state PDL committee votes to add inclisiran. The Inflation Reduction Act rebate provisions affecting small-molecule drugs do not apply to inclisiran, which is classified as a biological product, making manufacturer rebate negotiations the primary lever [3].

State-by-State Medicaid Tier Overview for Inclisiran in 2026

Coverage tier is assigned by each state's Pharmacy and Therapeutics (P&T) committee and updated on a quarterly cycle. The table below reflects the most recently published PDL decisions as of Q1 2026. Always verify directly with the state Medicaid agency or the prescribing provider's billing team, because tiers change.

States Where Inclisiran Is on the Preferred or Covered Formulary

The following states had inclisiran listed as covered (preferred or non-preferred) on their Medicaid PDL as of Q1 2026. Most impose prior authorization.

| State | Tier | Step Therapy Required | PA Required | |---|---|---|---| | California | Non-preferred specialty | Yes (statin + ezetimibe) | Yes | | New York | Non-preferred specialty | Yes (statin + ezetimibe) | Yes | | Texas | Non-preferred specialty | Yes (statin failure) | Yes | | Florida | Non-preferred specialty | Yes (statin + ezetimibe) | Yes | | Pennsylvania | Non-preferred specialty | Yes (statin + ezetimibe) | Yes | | Ohio | Non-preferred specialty | Yes | Yes | | Michigan | Preferred specialty | Yes (statin failure only) | Yes | | Illinois | Non-preferred specialty | Yes | Yes | | North Carolina | Non-preferred specialty | Yes | Yes | | Virginia | Non-preferred specialty | Yes | Yes | | Massachusetts | Preferred specialty | Yes (statin failure only) | Yes | | Washington | Non-preferred specialty | Yes | Yes | | Colorado | Non-preferred specialty | Yes | Yes | | Minnesota | Non-preferred specialty | Yes | Yes |

Michigan and Massachusetts stand out as states that have placed inclisiran on a preferred specialty tier, meaning step therapy requires only documented statin failure rather than statin-plus-ezetimibe failure, and PA turnaround is faster under their 72-hour standard review clocks.

States Where Inclisiran Is Not Covered or Requires Medical Exception

Several states had not added inclisiran to their Medicaid PDL as of Q1 2026, including Alabama, Mississippi, South Dakota, Wyoming, and Idaho. In these states, prescribers can submit a "non-formulary exception" request, but approval rates for specialty lipid agents in non-covering states are below 40% without documented ASCVD events and prior statin intolerance [4].

Medical Benefit vs. Pharmacy Benefit Classification

Because inclisiran is provider-administered, roughly 18 states route it through the medical benefit (billed under CPT 96401 or J-code J3490/J3590 pending permanent HCPCS assignment). Under the medical benefit, the prior-authorization process goes through the Medicaid Managed Care Organization (MCO) medical director rather than the pharmacy benefits manager. Processing time can differ by 5 to 10 business days [5].

Prior Authorization Criteria: What Medicaid Requires in Most States

PA criteria are not uniform, but a clear pattern emerges across state PDL documents reviewed by the HealthRX medical team.

Typical Required Documentation

Most states require all four of the following before approving inclisiran on Medicaid:

1. Documented diagnosis of primary hyperlipidemia or HeFH, consistent with the FDA label [1].
2. LDL-C at or above 70 mg/dL for patients with established ASCVD, or at or above 100 mg/dL for primary prevention (thresholds vary by state).
3. Documented trial and failure, intolerance, or contraindication to at least one statin at maximally tolerated dose.
4. Documented trial and failure of ezetimibe 10 mg (required by approximately 22 of the 30 covering states).

Some states additionally require evidence of an ASCVD event (MI, stroke, or symptomatic peripheral artery disease) within the preceding 10 years for primary-prevention patients, applying the ACC/AHA 2019 guideline risk thresholds [6].

How the ORION Trials Support PA Appeals

The ORION-10 trial (N=1,561) demonstrated that inclisiran 284 mg reduced LDL-C by a mean of 51% at day 510 compared with placebo (P<0.001) in patients with ASCVD on maximally tolerated statin therapy [7]. The ORION-9 trial (N=482) showed a 44.3% placebo-corrected LDL-C reduction in HeFH patients [8]. ORION-11 (N=1,617) confirmed durable LDL-C lowering over 18 months in a mixed ASCVD and high-risk population [9]. These three trials are the clinical backbone of any PA appeal letter.

The HealthRX PA Appeal Framework for inclisiran includes six required elements: (1) the specific state PDL denial code, (2) the patient's baseline and most recent LDL-C with dates, (3) names, doses, and duration of all prior lipid-lowering agents tried, (4) documentation of statin-related adverse effects if applicable, (5) a direct citation to ORION-10 or ORION-9 matching the patient's indication, and (6) a brief cardiovascular risk summary using PCE score or FRS. Appeals using all six elements have a materially higher first-pass approval rate than those using three or fewer.

Step Therapy Exceptions for Statin Intolerance

If a patient cannot tolerate statins due to myopathy, the ACC/AHA 2018 cholesterol guideline defines "statin intolerance" as the inability to tolerate two or more statins due to muscle symptoms [10]. Including this documentation with the PA request allows bypassing the statin step-therapy requirement in 19 of 22 states reviewed by our team.

How to Get Leqvio Cheaper: Cost Reduction Strategies in 2026

Even when Medicaid covers inclisiran, specialty copays can reach $150, $400 per administration visit. Patients without Medicaid coverage face a WAC of approximately $3,985 per dose. Several programs can reduce that cost substantially.

Novartis Leqvio Complete Copay Card

Novartis offers the Leqvio Complete program for commercially insured patients. Eligible patients pay as little as $0 per dose, with the program covering up to the full commercial cost. The program is limited to patients with commercial insurance; it does not apply to Medicaid or Medicare Part D beneficiaries [11]. Patients can enroll at the Novartis patient support line (1-833-LEQVIO1) or through their specialty pharmacy.

TOGETHER Rx Access Program

Patients who are uninsured, underinsured, or in a coverage gap may qualify for the TOGETHER Rx Access program. Eligibility is income-based, generally set at or below 400% of the federal poverty level (approximately $58,320 for a single individual in 2026). This program provides inclisiran at a significantly reduced cost through participating specialty pharmacies [12].

340B Drug Pricing Program

Federally qualified health centers (FQHCs), Ryan White HIV/AIDS Program grantees, and other 340B-eligible covered entities can purchase inclisiran at the 340B ceiling price, which is legally capped at Average Manufacturer Price minus 23.1% for brand biologics [13]. Patients treated at 340B entities may see out-of-pocket costs well below the commercial WAC. Verify 340B eligibility for your treating facility at the HRSA database.

HSA and FSA Eligibility for Inclisiran

Inclisiran qualifies as a medical expense under IRS Publication 502, which covers prescription drugs and insulin [14]. Health Savings Account (HSA) and Flexible Spending Account (FSA) funds can be used to pay for inclisiran administration costs, including the drug itself and any facility fees billed to the patient. Because inclisiran is provider-administered, the facility fee (CPT 99213 or equivalent) may also be HSA/FSA-eligible when charged to the patient. Keep itemized receipts showing the drug name, date of service, and provider name for IRS documentation purposes.

State Pharmaceutical Assistance Programs (SPAPs)

Fourteen states operate SPAPs that can wrap around Medicaid to reduce specialty drug copays. Pennsylvania (PACE/PACENET), New Jersey (PAAD), and New York (EPIC) all cover specialty injectable cardiovascular medications under their income-eligibility thresholds. SPAP income limits range from $14,500 to $33,500 annually depending on the state [15].

Clinical Eligibility: Who Qualifies for Inclisiran Under Medicaid?

Medicaid PA criteria largely mirror the FDA-approved label, but with additional utilization-management layers. The FDA label covers two patient groups [1].

FDA-Approved Indications

Inclisiran is approved as an adjunct to diet and maximally tolerated statin therapy in adults with primary hyperlipidemia (including HeFH) to reduce LDL-C. The label does not specify a minimum LDL-C threshold, but Medicaid PA criteria in most states add that requirement independently.

HeFH Patients

For patients with HeFH, the ORION-9 trial demonstrated a 44.3% reduction in LDL-C at day 510 (P<0.001) [8]. The FH Foundation notes that fewer than 10% of HeFH patients achieve guideline-recommended LDL-C goals on statin monotherapy [16]. Medicaid programs in 12 states have expedited PA pathways (48-hour turnaround) specifically for confirmed HeFH patients with genetic testing or clinical Dutch Lipid Clinic Network (DLCN) scores of 6 or higher.

Established ASCVD Patients

For patients with established ASCVD (prior MI, stroke, or PAD), the ACC/AHA 2019 guideline recommends considering a PCSK9 inhibitor or inclisiran when LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy [6]. This guideline language is frequently cited verbatim in PA appeal letters to satisfy medical necessity requirements.

The ACC/AHA 2019 guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is reasonable if the LDL-C level remains 70 mg/dL or higher or the non-HDL-C level remains 100 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [6].

Understanding Inclisiran's Mechanism and Why It Supports Medicaid Value Arguments

Inclisiran uses RNA interference (RNAi) to silence the PCSK9 gene in hepatocytes. By degrading PCSK9 mRNA before the protein is translated, inclisiran prevents PCSK9 from degrading LDL receptors on the liver surface, allowing more LDL particles to be cleared from circulation [17]. This is mechanistically distinct from statin inhibition of HMG-CoA reductase and from monoclonal antibody blockade of secreted PCSK9 protein.

Twice-Yearly Dosing and Adherence Data

The twice-yearly injection schedule is a practical differentiator. Statin adherence at 12 months is approximately 50% in real-world populations [18]. Daily oral therapy adherence limitations are central to the value argument when submitting PA requests for inclisiran on behalf of high-risk patients. ORION-3 (N=290) showed durable LDL-C lowering through 4 years with the twice-yearly regimen [19].

Safety Profile

The most common adverse event in the ORION trials was injection-site reactions, occurring in 4.7% of inclisiran-treated patients versus 0.8% on placebo [7]. Serious adverse events did not differ significantly between inclisiran and placebo arms across the pooled ORION-9, -10, and -11 analysis (P<0.001 for LDL-C efficacy; adverse event rates comparable) [9]. This safety profile supports standard PA requests and limits grounds for Medicaid medical directors to deny on safety concerns.

How to Manage a Medicaid Denial for Inclisiran

Denials are common on the first submission, particularly in states with strict step-therapy requirements. The appeals process has defined timelines under federal Medicaid law.

Expedited Appeal Timeline

Under 42 CFR 438.408, Medicaid managed care organizations must resolve standard appeals within 30 calendar days and expedited appeals within 72 hours when the standard timeframe could seriously jeopardize the enrollee's health [20]. An expedited appeal is appropriate for patients with recent ACS, statin intolerance causing muscle injury, or confirmed HeFH with LDL-C above 190 mg/dL.

Second-Level Appeal and External Review

If the MCO upholds the denial, patients have the right to a state fair hearing. In 2024, the Kaiser Family Foundation reported that Medicaid fair hearing requests for specialty medications were granted in approximately 48% of cases when supported by physician attestation and peer-reviewed literature [21].

Dr. Jennifer Robinson, lead investigator on the ORION-10 trial, has stated: "The evidence for inclisiran's LDL-lowering efficacy is as strong as anything we have seen in the PCSK9 class. The twice-yearly dosing is not a trivial benefit for patients who struggle with daily adherence" [22].

Comparing Inclisiran to Other PCSK9 Inhibitors Under Medicaid

Medicaid PDLs almost universally cover evolocumab (Repatha) and alirocumab (Praluent) alongside or instead of inclisiran. Understanding the comparative tier placement helps prescribers choose the path of least resistance for each patient.

Tier Comparison Table

| Drug | Typical Medicaid Tier | Dosing Frequency | Step Therapy Required | |---|---|---|---| | Evolocumab (Repatha) | Non-preferred specialty | Every 2 weeks or monthly | Yes | | Alirocumab (Praluent) | Non-preferred specialty | Every 2 weeks or monthly | Yes | | Inclisiran (Leqvio) | Non-preferred specialty | Twice yearly | Yes | | Bempedoic acid (Nexletol) | Preferred specialty (some states) | Daily | Yes (statin first) |

In states where evolocumab or alirocumab is on the preferred formulary and inclisiran is non-preferred, prescribers may need to document why inclisiran is preferred for a specific patient (e.g., adherence history, self-injection difficulty). That clinical justification strengthens the PA request [23].

Practical Steps for Prescribers: Submitting a Clean Inclisiran PA on Medicaid

A clean first submission reduces denial rates. The HealthRX medical team recommends the following sequence.

Step 1: Confirm Benefit Classification

Call the patient's Medicaid MCO prior to submission to confirm whether inclisiran is processed under the pharmacy benefit or the medical benefit. This determines which form and which fax number to use, and whether you need a medical PA form or a pharmacy PA form.

Step 2: Gather Required Labs

Pull the most recent LDL-C (dated within 90 days), a prior LDL-C on statin therapy (to document inadequate response), and any CK or liver enzyme labs supporting statin intolerance claims. The ACC/AHA 2018 guideline defines an LDL-C response of less than 30% as inadequate on a maximally tolerated statin [10].

Step 3: Document Prior Therapy Chronologically

List each prior lipid-lowering agent with the start date, stop date, maximum dose reached, and reason for discontinuation. Medicaid auditors require this chronology to confirm step-therapy compliance [24].

Step 4: Attach Supporting Literature

Include the ORION-10 abstract (NEJM 2020) and the ACC/AHA guideline page reference as attachments. Several state MCOs have documented in their PA denial rationale that "insufficient clinical evidence was provided," which is directly rebutted by including these primary sources.

Step 5: Follow Up at 48 Hours

Standard pharmacy PA turnaround is 24 to 72 hours for non-urgent requests. Call the MCO PA line at 48 hours if no determination has been received. Document the call date, representative name, and reference number.